| Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. | |
| | |
MedLine Citation:
|
PMID: 22984206 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVES: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. METHODS: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. RESULTS: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number <50 copies/mL was 4.1 months (95% CI 3.5-4.6) in non-coinfected patients and 3.9 months (95% CI 3.3-4.5) in coinfected patients (hazard ratio 1.039, 95% CI 0.761-1.418, P = 0.766, log-rank test). The risk of developing new grade 3-4 hepatic adverse events was significantly higher in coinfected patients (hazard ratio 1.779, 95% CI 1.123-2.817, P = 0.009). The two groups of coinfected and non-coinfected patients had similar rates of interruption of any baseline drug (hazard ratio 1.075, 95% CI 0.649-1.781, P = 0.776) and of raltegravir (hazard ratio 1.520, 95% CI 0.671-3.447, P = 0.311). Few AIDS-defining events and deaths occurred. CONCLUSIONS: Viroimmunological response to regimens based on raltegravir and other recent anti-HIV inhibitors is not negatively affected by coinfection with HBV or HCV. Liver toxicity, either pre-existing or new, is more common in coinfected patients, but with no increased risk of treatment interruption. |
| | |
Authors:
|
Liliana Elena Weimer; Vincenzo Fragola; Marco Floridia; Giovanni Guaraldi; Nicoletta Ladisa; Daniela Francisci; Rita Bellagamba; Anna Degli Antoni; Giustino Parruti; Andrea Giacometti; Paolo Emilio Manconi; Angela Vivarelli; Gabriella D'Ettorre; Maria Stella Mura; Stefania Cicalini; Roberta Preziosi; Laura Sighinolfi; Gabriella Verucchi; Raffaella Libertone; Marcello Tavio; Loredana Sarmati; Raffaella Bucciardini; |
Related Documents
:
|
9563236 - Group psychotherapy for persons with hiv and aids-related illnesses. 16898846 - A comparative review of health-related quality-of-life measures for use in hiv/aids cli... 16900276 - Changes in symptoms and health-related quality of life in a nationally representative s... 23613886 - Survival in liver transplant recipients with hepatitis b- or hepatitis c-associated hep... 7769376 - Induction of asymptomatic hbeag carrier state in a patient with down's syndrome followi... 9563236 - Group psychotherapy for persons with hiv and aids-related illnesses. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-9-14 |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: - ISSN: 1460-2091 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-9-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Complete nucleotide sequence of pHN7A8, an F33:A-:B-type epidemic plasmid carrying blaCTX-M-65, fosA...
Next Document: Are Self-Management Interventions Suitable for All? Comparing Obese Versus Nonobese Type 2 Diabetes ...